MELISSA MATINA: Open Payments
NPI 1003324526 · CLIFTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,297 in 71 payments from 23 companies in 2025. Trend: 2023 $622 · 2024 $903 · 2025 $1,297
Food & beverage: $1,297
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 11 | $175 |
| Novo Nordisk Inc | 7 | $143 |
| Chiesi USA, Inc. | 2 | $115 |
| ABBVIE INC. | 6 | $98 |
| Antares Pharma, Inc. | 6 | $97 |
| Tandem Diabetes Care, Inc. | 3 | $77 |
| AstraZeneca Pharmaceuticals LP | 5 | $76 |
| Lilly USA, LLC | 3 | $55 |
| Corcept Therapeutics | 3 | $52 |
| Ascendis Pharma Endocrinology Inc | 3 | $47 |
Products named: MYCAPSSA, XYOSTED, EVENITY, t:slim X2 Insulin Pump with Control-IQ, Wegovy, Korlym, SYNTHROID, REPATHA.
Industry payments across NJ — which companies pay providers there.
